Page 19 - Labatt Brain Tumour Research Centre Annual Report 2023 to 2024

W
Dr. Cynthia Hawkins
Elucidating the altered metabolism of diffuse
midline glioma. Meagan’s HUG (Meagan Bebenek
Foundation)
Transforming outcomes for adolescents and young
adults with brain tumors. Canadian Cancer Society.
Liquid biopsy for pediatric cancer. SickKids Garron
Family Cancer Centre
Targeting METTL13 for the treatment of diffuse
midline glioma. Ontario Institute for Cancer
Research (OICR)
Tracing the origins of DIPG. ChadTough Defeat
DIPG Foundation
HSP90 inhibitor PU-HZ151 as a novel therapy for
DIPG. Meagan’s HUG (Meagan Bebenek Foundation)
Molecular and clinical characterization of
disseminated pediatric low grade glioma.
Vanderbilt University Medical Center
Proteogenomic precision medicine-based adaptive
clinical trial for DIPG. We Love You Connie
Foundation
Integrated characterization of disseminated
paediatric low-grade glioma. Rally Foundation for
Childhood Cancer Research, Pediatric Brain Tumor
Foundation
Lowpass genomic instability characterization as
a comprehensive cancer and germline diagnostic
assay. Genome Canada & Ontario Genomics
Institute, Genomic Applications Partnership
Program (GAPP)
Synthetic lethality screening with methionine
restriction for treatment of DIPG. The Cure Starts
Now Foundation
Next generation precision oncology for pediatric-
type AYA gliomas. Canadian Institutes of Health
Research
Investigating diffuse midline glioma evolution and
treatment resistance. Canadian Institutes of Health
Research
A phase 2 study of Trametinib for patients with
pediatric glioma or plexiform neurofibroma with
refractory tumour and activation of the MAPK/ERK
pathways. Canadian Institutes of Health Research
Dr. Annie Huang
A C17 babybrains DECRYPT feasibility trial for
children <6 yrs. old with high-risk embryonal brain
tumors. CIHR Pediatric Cancer Initiative/ACCESS &
Cancer Research Society
A global platform for translational research in rare
pediatric brain tumors. US Department of Defense
Rare Cancers Research Program
Molecular prognosticators for rare embryonal
brain tumors in the HS4 trial. Rally Foundation for
Childhood Cancer Research
New mouse models and targeted therapies
for aggressive forms of germline and sporadic
pineoblastoma. Canadian Institutes of Health
Research
Delineating mechanisms of cellular and phenotypic
heterogeneity in ETMRs. Canadian Institutes of
Health Research
Molecular basis of clinical heterogeneity in
rhabdoid brain tumours. Canadian Institutes of
Health Research
Establishing an ETMR zebrafish model.
b.r.a.i.n.child
Dr. Xi Huang
Identifying small molecule potassium channel
inhibitors as novel cancer therapeutics. SickKids
Commercial Proof of Principle Grant (SickKids
Breakthrough Fund)
Enhancing blood-tumor barrier permeability to
increase therapy response. Cancer Research Society
Targeting ion channel LRRC8A to increase blood-
tumor barrier permeability and therapy response
of medulloblastoma. SickKids Garron Family
Cancer Centre Pitblado Discovery Grant
Targeting blood-tumor barrier to activate the
immune microenvironment of pediatric brain tumor
Meagan’s HUG (Meagan Bebenek Foundation)
Targeting potassium channel to disrupt the
cellular hierarchy and suppress malignant growth
of pediatric brain tumor. Canadian Institutes of
Health Research
19